Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683926 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL10224384 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL2685419 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL16377662 | 0.84 | PKM (0.39) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL16377663 | 0.81 | FPR2 (0.49) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL855772 | 0.81 | FPR2 (0.49) | PPM1BPTPN1PPP1CCPKMFPR2 | |
| SCHEMBL856527 | 0.80 | FPR2 (0.56) | PKMFPR2SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL8547143 | 0.80 | FPR2 (0.56) | PKMFPR2SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL855208 | 0.77 | SMN1; SMN2 (0.37) | PKMFPR2SMN1; SMN2FPR3 | |
| SCHEMBL2683203 | 0.77 | SMN1; SMN2 (0.37) | PKMFPR2SMN1; SMN2FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | PPM1B 4312/4885PTPN1 2506/4885PPP1CC 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.